Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Translation Initiation Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for EIF4E drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | EIF4E Wild-Type & Mutant Proteins (S209A, S209D) High purity (>95%), Endotoxin Controlled. Sequence Verified. Suitable for SPR/MST binding assays. |
View EIF4E Products |
| Gene Delivery | EIF4E Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression validation. |
View EIF4E Products |
| Benchmark Ab | Anti-EIF4E Recombinant Antibody Recombinant positive control for Western Blot, IHC, and IP assays. |
View EIF4E Products |
| Validator | EIF4E siRNA Set For target knockdown verification and target validation assays. |
View EIF4E Products |
| Related Target A | EIF4A RNA helicase component of the eIF4F complex; synergistic target for translation initiation inhibition. |
View EIF4A Products |
| Related Target B | EIF4G Scaffold protein of the eIF4F complex; critical for EIF4E-EIF4G interaction disruption assays. |
View EIF4G Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cap-binding Pocket Mimicry | Recombinant EIF4E proteins with confirmed theoretical MW and high purity (>95%) to ensure consistent m7G cap affinity. |
| Phosphorylation-State Screening (S209) | S209A (constitutively inactive) and S209D (phospho-mimetic) mutant panels strictly verified by mass spectrometry. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live EIF4E R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for EIF4E therapeutics is intensifying, with major players shifting focus from traditional systemic kinase inhibition (e.g., MNK1/2 inhibitors) to direct EIF4E small molecule inhibitors, PROTACs, and antisense oligonucleotides (ASOs). As first-generation therapies reach the clinic, the next wave of R&D is targeting the direct disruption of the eIF4F translation initiation complex and the selective degradation of EIF4E to overcome resistance in KRAS, MYC, and BRAF-driven malignancies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor (Cap-competitors) | Effector Therapeutics, Boehringer Ingelheim | Solid Tumors, Colorectal Cancer, NSCLC | Cap-binding disruption assay (Need high-purity EIF4E WT protein) |
| PROTAC / Degrader | Arvinas, C4 Therapeutics | Hematological Malignancies, Breast Cancer | Ubiquitination & degradation assays (Need Lentivirus for stable reporter lines) |
| eIF4F Complex Disruptor | Academic Consortia, Biotech Startups | Refractory Solid Tumors | Protein-Protein Interaction (PPI) screening (Need recombinant EIF4E & EIF4G) |